Ambitions of CVS Health Corporation (CVS) are elevated despite pressure on its PBM units as reflected in its increased price target. Various stakeholders including BI Asset Management, Parkwood LLC, State Street Corp, Quantinno Capital Management LP, Natixis, Daiwa Securities Group Inc, Ariel Investments LLC, Investment Management Corp of Ontario, and Cerity Partners LLC have boosted their holdings in CVS. The company's 2026 profit forecasts surpass estimates, indicating positive momentum in its turnaround plan which is further verified by its stock performance and 2025 guidance. Meanwhile, CVS has agreed to pay $5M and $37.8M settlements linked to prescription reimbursement and insulin pen fraud allegations respectively. Bernstein, Mizuho, UBS, TD Cowen, Jefferies, Truist, and Barclays have raised their price targets for CVS. As part of its growth strategy, CVS has launched new Workforce Innovation and Talent Centers in Fort Worth and Chicago and completed the acquisition of Rite Aid assets nationwide.
Cvs Health Corporation CVS News Analytics from Fri, 04 Apr 2025 14:14:51 GMT to Sat, 13 Dec 2025 09:48:50 GMT - Rating 8 - Innovation 2 - Information 9 - Rumor -1
